WHO approves India's Covaxin vaccine for emergency use

Source : 112 Ukraine

According to the WHO, the benefits far outweighed the risks
18:55, 3 November 2021

Open source

The World Health Organization (WHO) has granted approval for emergency authorization to Covaxin vaccine co-developed by India’s medical-research agency and local manufacturer Bharat Biotech International Ltd, the WHO said in a tweet.

The vaccine was approved in India in January while the third phase of clinical trials was still under way, sparking some concern and criticism.

Related: Only vaccinated, holders of negative PCR tests or Covid certificates to be allowed in Parliament building

Bharat Biotech, which makes the vaccine, has since published data suggesting 78% efficacy.

The WHO's expert panel, which authorises emergency approvals, had asked for more data last month while examining the application Bharat Biotech had filed in July.

In its approval it said:

  • The vaccine was recommended for use in two doses, with a dose interval of four weeks, in all age groups 18 and above
  • Covaxin had 78% efficacy against Covid 19 of any severity, 14 or more days after the second dose, and is extremely suitable for low- and middle-income countries due to easy storage requirements
  • Available data on vaccination of pregnant women with the vaccine are insufficient to assess vaccine safety or efficacy in pregnancy 
Система Orphus

If you find an error, highlight the desired text and press Ctrl + Enter, to tell about it

see more